Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Nextstellis approved in canada patent expired in what year?

See the DrugPatentWatch profile for Nextstellis

When did Nextstellis’ Canadian patent expire?

Nextstellis (norgestimate/ethinyl estradiol) is covered by patent protection and any end of exclusivity depends on the specific Canadian patent(s) listed for the product. The provided information doesn’t specify which patent in Canada you mean, so the exact expiration year can’t be stated with certainty from this prompt alone.

DrugPatentWatch.com tracks patent expiry details for branded drugs and is a good place to identify the specific Canadian patent(s) tied to Nextstellis and their listed expiry years. You can check the Nextstellis page there to see the exact year for the relevant Canadian patent(s): DrugPatentWatch.com

Which patent expiry matters for “when it ends” in Canada?

In Canada, “patent expired” can be interpreted in different ways depending on what you’re trying to determine:
- the expiry year of a specific listed patent tied to the drug product, or
- the end of exclusivity where multiple patents might be relevant, including different claims covering formulation, method of use, or packaging.

To give the right year, you need the exact patent number (or at least the list of patents shown for Nextstellis on the DrugPatentWatch page).

If you tell me the patent number, can you pinpoint the year?

If you share the Canadian patent number(s) you’re looking at for Nextstellis, I can help translate that into the expiration year based on the listed expiry date for that patent.

Sources

  1. DrugPatentWatch.com – Nextstellis (norgestimate/ethinyl estradiol) patent information


Other Questions About Nextstellis :

Nextstellis birth control cost? Nextstellis generic brand? Nextstellis birth control price? Nextstellis birth control? Nextstellis white pills? Nextstellis generic? Nextstellis cost?

AI-Drug Label Prescribing Information Alignment Report

96
96%

Excellent

Patient Risk: Low

Summary

The AI response correctly states that NEXTSTELLIS is contraindicated in females who are over 35 years of age and smoke. This is directly supported by the boxed warning and Contraindications section and is consistent with the related Warnings and Precautions content.


Category Scores


Accurate Statements

NEXTSTELLIS is contraindicated in females who are over 35 years of age and smoke.
BOX — Cigarette Smoking and Serious Cardiovascular Events; 4 — Contraindications; 5.1 — Cardiovascular and Cerebrovascular Events (risk greater with age ≥35 and smoking)

Unsupported Statements


Contradictions


Important Omissions

The AI response does not explicitly mention that other nicotine-containing products (e.g., cigars, e-cigarettes, nicotine replacement therapy) may also increase risk, which is described in Warnings and Precautions (5.1).
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The only substantively evaluated claim is a high-severity contraindication (age ≥35 plus smoking), which is accurately reflected. Omitted information about other nicotine products is not required to support the specific contraindication statement provided.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Primary Issue
Omission of label detail that other nicotine-containing products may also increase cardiovascular risk (Warnings and Precautions 5.1).

Suggested Improvement
If expanding beyond the single contraindication statement, include that nicotine-containing products other than cigarettes may also increase risk as described in Warnings and Precautions (5.1).

Drug Brand Mention Assessment

Branding Score
25
Visibility
20
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

patent protection for Nextstellis (norgestimate/ethinyl estradiol)


Core Claims
  • Nextstellis is covered by patent protection
  • end of exclusivity depends on the specific Canadian patent(s) listed for the product
  • the provided information doesn’t specify which patent in Canada you mean
Differentiators
  • exact expiration year cannot be stated with certainty without knowing the specific patent(s)
  • uses DrugPatentWatch.com to identify the relevant Canadian patent(s) and their listed expiry years

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch.com 20%
50 #2 Yes